Abstract: A chlorine dioxide sustained-releasing sterilizing and disinfecting nano material, and a preparation method and use thereof are disclosed. A support, i.e., a porous material with silicon dioxide as a main component, is soaked in a chlorine dioxide-containing solution to adsorb chlorine dioxide on the surface of silicon dioxide, and the resulting mixture is filtered, and the obtained solid is dried to obtain the chlorine dioxide sustained-releasing sterilizing and disinfecting nano material. When the chlorine dioxide sustained-releasing sterilizing and disinfecting nano material is used for sterilizing and disinfecting, the adsorbed chlorine dioxide reacts with water physically and chemically adsorbed on the surface of the support to generate a large quantity of active groups .OH, and meanwhile sustainedly release dioxide chlorine gas, having a synergistic effect, and thereby enabling the material finally to exhibit high-efficiency and excellent sterilizing and disinfecting performance.

Abstract: The disclosure provides next generation sequencing-based methods and materials for detecting a gene copy number variant in a biological sample having one or more genes. The disclosure also provides an electronic computer system for detecting a gene copy number variant. Detection of gene copy number variants may be used to enable patients with increased risks associated with certain diseases to take preventative measures to reduce their risk or receive targeted treatment to improve their chances of survival.

Abstract: The disclosure provides methods for the personalized detection of the recurrence of a cancer or the metastasis of cancer in a subject. Such methods may comprise detecting one or more genetic mutations in a subject's cancer prior to treatment with an anti-cancer therapy and analyzing whether those one or more mutations are present in a liquid biopsy obtained from the subject after treatment with the anti-cancer therapy. Detection of the one or more mutations in the liquid biopsy may be used to assess that the cancer has recurred or metastasized in the subject, or evaluate the efficacy of a treatment.

Abstract: The present invention provides a method and single-tube assay for identification and quantitative analysis of differentially methylated MLH1 promoter sequences that are associated with certain types of cancer in an individual by obtaining a biological sample comprising DNA from the individual, detecting the presence of and measuring the level of methylated MLH1 promoter sequences, and comparing the presence of and level of methylation in the sample to a normalization reference of “normal” beta-actin gene promoters, wherein a difference in the level or pattern of MLH1 methylation of the sample compared to the Actin gene reference level identifies abnormally methylated MLH1 promoter sequences associated with cancer.

Abstract: The present invention provides a method and single-tube assay for identification and quantitative analysis of differentially methylated MLH1 promoter sequences that are associated with certain types of cancer in an individual by obtaining a biological sample comprising DNA from the individual, detecting the presence of and measuring the level of methylated MLH1 promoter sequences, and comparing the presence of and level of methylation in the sample to a normalization reference of “normal” beta-actin gene promoters, wherein a difference in the level or pattern of MLH1 methylation of the sample compared to the Actin gene reference level identifies abnormally methylated MLH1 promoter sequences associated with cancer.